BiotechTube

alefacept

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Oct 1, 2007 → Dec 1, 2009

NCT ID
NCT00658606

About alefacept

alefacept is a approved stage product being developed by Astellas Pharma for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00658606. Target conditions include Plaque Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Plaque Psoriasis were approved

Approved (20) Terminated (6) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved
✅Topicort® (desoximetasone) Topical Spray, 0.25%Sun PharmaceuticalApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
✅IxekizumabEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT01267643Phase 1Terminated
NCT01226420Phase 2Terminated
NCT00808223Phase 2Completed
NCT00815633ApprovedTerminated
NCT00953329ApprovedTerminated
NCT00832585ApprovedCompleted
NCT00658606ApprovedCompleted
NCT00168753ApprovedCompleted
NCT00674063Phase 3Completed
NCT00692172Phase 3Completed

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
35
AlefaceptAstellas PharmaApproved
43
Halobetasol PropionateSun PharmaceuticalPhase 2
27
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXSSun PharmaceuticalPhase 2
35
DSXS topicalSun PharmaceuticalPhase 2
35
Halobetasol Topical LotionSun PharmaceuticalApproved
35
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
40
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
35
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
40
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
40
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32
Topical TA-102 A + Topical TA-102 B + Topical TA-102 C + Topical TA-102 D + Topical TA-102 ESun PharmaceuticalPhase 1
29